Camphor | hsa00514 | Other types of O-glycan biosynthesis | 3.20E-02 | 2 | O15294, Q9NY28 | OGT, GALNT8 | More | |
Camphor | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.20E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Camphor | hsa00982 | Drug metabolism - cytochrome P450 | 3.20E-02 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Camphor | hsa01524 | Platinum drug resistance | 3.62E-02 | 4 | Q13489, P98170, P78417, P43246 | BIRC3, BIRC4, GSTO1, MSH2 | More | |
Camphor | hsa04014 | Ras signaling pathway | 4.38E-02 | 5 | P20827, P49767, Q14644, P0DP23, P62873 | EFNA1, VEGFC, RASA3, CALM1, GNB1 | More | |
Camphor | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | |
Camphor | hsa04371 | Apelin signaling pathway | 9.26E-03 | 5 | P62873, Q13485, P84022, Q16566, P0DP23 | GNB1, SMAD4, SMAD3, CAMK4, CALM1 | More | |
Camphor | hsa04640 | Hematopoietic cell lineage | 1.64E-03 | 2 | P04234, P20036 | CD3D, HLA-DPA1 | More | |
Camphor | hsa04657 | IL-17 signaling pathway | 3.62E-02 | 4 | P08238, Q07955, Q9UJX4, P04141 | HSP90AB1, SFRS1, ANAPC5, CSF2 | More | |
Camphor | hsa04658 | Th1 and Th2 cell differentiation | 1.85E-03 | 2 | P04234, P20036 | CD3D, HLA-DPA1 | More | |
Camphor | hsa04659 | Th17 cell differentiation | 1.64E-03 | 2 | P20036, P04234 | HLA-DPA1, CD3D | More | |
Camphor | hsa04672 | Intestinal immune network for IgA production | 3.16E-02 | 1 | P20036 | HLA-DPA1 | More | |
Camphor | hsa04744 | Phototransduction | 5.92E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | |
Camphor | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.93E-02 | 1 | Q9Y5S1 | TRPV2 | More | |
Camphor | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.33E-02 | 4 | P84022, Q13485, Q12778, P49767 | SMAD3, SMAD4, FOXO1, VEGFC | More | |
Camphor | hsa04940 | Type I diabetes mellitus | 4.05E-02 | 1 | P20036 | HLA-DPA1 | More | |
Camphor | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | |
Camphor | hsa05034 | Alcoholism | 4.38E-02 | 5 | Q16566, P0DP23, P62873, O60814, P68431 | CAMK4, CALM1, GNB1, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Camphor | hsa05133 | Pertussis | 1.88E-02 | 3 | P11215, P0DP23, P23528 | ITGAM, CALM1, CFL1 | More | |
Camphor | hsa05142 | Chagas disease | 4.93E-02 | 1 | P04234 | CD3D | More | |
Camphor | hsa05166 | Human T-cell leukemia virus 1 infection | 9.87E-03 | 2 | P04234, P20036 | CD3D, HLA-DPA1 | More | |
Camphor | hsa05169 | Epstein-Barr virus infection | 3.43E-03 | 2 | P20036, P04234 | HLA-DPA1, CD3D | More | |
Camphor | hsa05200 | Pathways in cancer | 6.17E-03 | 12 | Q13751, P08238, P43246, P84022, Q13485, Q13489, P98170, P49767, Q12778, P62873, P78417, P0DP23 | LAMB3, HSP90AB1, MSH2, SMAD3, SMAD4, BIRC3, BIRC4, VEGFC, FOXO1, GNB1, GSTO1, CALM1 | More | |
Camphor | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.93E-02 | 1 | P04234 | CD3D | More | |
Camphor | hsa05310 | Asthma | 2.71E-02 | 1 | P20036 | HLA-DPA1 | More | |
Camphor | hsa05320 | Autoimmune thyroid disease | 3.60E-02 | 1 | P20036 | HLA-DPA1 | More | |
Camphor | hsa05321 | Inflammatory bowel disease | 4.05E-02 | 1 | P20036 | HLA-DPA1 | More | |
Camphor | hsa05330 | Allograft rejection | 3.60E-02 | 1 | P20036 | HLA-DPA1 | More | |
Camphor | hsa05332 | Graft-versus-host disease | 4.05E-02 | 1 | P20036 | HLA-DPA1 | More | |
Camphor | hsa05340 | Primary immunodeficiency | 1.81E-02 | 1 | P04234 | CD3D | More | |
Camphor | hsa05416 | Viral myocarditis | 4.49E-02 | 1 | P20036 | HLA-DPA1 | More | |